Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pulmodexane is a medication containing dextromethorphan hydrobromide, which functions as an antitussive (cough suppressant). It's primarily marketed in France and is used to treat dry, irritating coughs. Dextromethorphan is a non-opioid antitussive that works by affecting the signals in the brain that trigger the cough reflex. Its major metabolite, dextrorphan, binds with high affinity to σ-receptors to produce antitussive activity without exhibiting classic opiate effects that occur from binding to μ- and δ-receptors. At therapeutic doses, it doesn't cause respiratory depression or dependence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pulmodexane.